Last reviewed · How we verify
NCT07149038
Evaluation of Cerogrin for Auricular Vagus Nerve Stimulation in Vascular Dementia or Vascular Mild Cognitive Impairment
NA trial testing Cerogrin in Vascular Dementia in 24 participants. Currently enrolling.
30 June 2026
Quick facts
| Lead sponsor | Neurogrin Inc. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 15 October 2025 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Cerogrin
- Sham Device — full drug profile →
Conditions studied
- Vascular Dementia — all drugs for Vascular Dementia →
- Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Sponsor
Neurogrin Inc.
Who can join
Adults 55 to 89, any sex, with Vascular Dementia or Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial evaluates the preliminary effectiveness and safety of Cerogrin, a medical device developed by Neurogrin Inc. for auricular vagus nerve stimulation, in patients with vascular dementia or vascular mild cognitive impairment. Given the limited availability of effective pharmacological treatments for these conditions, the study aims to assess whether Cerogrin can enhance cognitive function through non-invasive neuromodulation. Twenty-four participants will be randomized to receive either the active Cerogrin device or a sham (non-stimulating) device. Daily use will occur at home for 30 minutes over a four-week intervention period. The full study duration, including baseline assessments and follow-up, will span up to three months. During this period, cognitive function, neural activity, and safety outcomes will be systematically evaluated. This feasibility trial represents a critical step toward expanding therapeutic options for vascular cognitive impairment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07149038
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vascular Dementia
Currently open trials in the same condition.
- NCT06298474 — The BRAIN App (Phase 2 SBIR) · NA · recruiting
- NCT06862557 — Pulsed Electromagnetic Field Treatment With Dementia Patients · NA · recruiting
- NCT06416371 — Retinal Vessel Leakage in Cerebral Small Vessel Disease · recruiting
- NCT07259499 — Predictors of Emergency Department Use in Frail Patients · recruiting
- NCT06122415 — The Swedish BioFINDER - Memory Clinic Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07149038 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Neurogrin Inc.
- Last refreshed: 18 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07149038.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing